Newsfiscal.ai
Ascendiant Capital Maintains Buy Rating and Raises Price Target for NRx Pharmaceuticals
· Published
Article summary
Ascendiant Capital has reaffirmed its Buy rating on NRx Pharmaceuticals and increased its price target to $51.00 from $50.00.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…